<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303769</url>
  </required_header>
  <id_info>
    <org_study_id>GL2702-301</org_study_id>
    <nct_id>NCT02303769</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS</brief_title>
  <acronym>GL2702</acronym>
  <official_title>A Multicenter, Randomized, Double -Blind, Parallel, Comparative, Phase III Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1 Tablet in BPH Patients With LUTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GL Pharm Tech Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to investigate the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D - tablet
      in benign prostatic hyperplasia patients with lower urinary tract symptomatic
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GL2702 GLARS-NF1 tablet is controlled released formation which is made by GL Pharm Tech
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to endpoint in total International Prostate Symptom Score</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in total International Prostate Symptom Score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in voiding score</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in IPSS QoL</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in Qmax</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in PVR</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to event/proportion of subjects with AUR</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to event/proportion of subjects undergoing BPH related prostatic surgery</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">309</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tamsulosin HCL 0.2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Harnal-D tablet (Tamsulosin HCL 0.2mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin HCL 0.4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GL2702 GLARS-NF1 tablet (Tamsulosin HCL 0.4mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin HCL 0.4mg</intervention_name>
    <description>Tamsulosin HCL 0.4mg once a day</description>
    <arm_group_label>Tamsulosin HCL 0.4mg</arm_group_label>
    <other_name>GL2702 GLARS-NF1 Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin HCL 0.2mg</intervention_name>
    <description>Tamsulosin HCL 0.2mg once a day</description>
    <arm_group_label>Tamsulosin HCL 0.2mg</arm_group_label>
    <other_name>Harmal D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 50 years old, BPH diagnosted, Adult Male Subject

          -  IPSS ≥ 13 point

          -  PSA &lt; 4ng/mL

          -  5ml/sec &lt; Qmax ≤ 15ml/sec

        Exclusion Criteria:

          -  Prostatic cancer

          -  250ml &lt; PVR

          -  ALT or AST &gt; 2 times (Upper Normal Range)

          -  Total Bilirubin &gt; 1.5 times (Upper Normal Range)

          -  Treated with α-adrenalin receptor blocker within 2weeks before screening

          -  Treated with 5Alpha-Reductase Inhibitor within 6 months before screening

          -  Treated with phytotherapy within 2weeks before screening

          -  Treated with Anabolic Steroid within 6 months before screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You T Gun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eulji General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eulji general hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lower Urinary Track Syndrome</keyword>
  <keyword>Harnal</keyword>
  <keyword>Tamsulosin HCL 0.4mg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

